Xingnaojing injection

DRUG5 trials

Sponsors

Capital Medical University, Dongzhimen Hospital, Beijing, Ying Gao

Conditions

Acute Ischemic StrokeAcute StrokeIntracerebral HemorrhageIschemic StrokeIschemic Stroke, AcuteStroke, AcuteStroke, Ischemic

Phase 1

Deferoxamine and Xingnaojing Injection Treatment in Intracerebral Hemorrhage

Capital Medical UniversityIntracerebral Hemorrhage

Start: 2015-03-31End: 2016-12-31Target: 180Updated: 2015-05-18

Phase 4

Xingnaojing for Moderate-to-severe Acute Ischemic Stroke (XMAS)

Dongzhimen Hospital, BeijingAcute Ischemic Stroke

Start: 2016-03-31End: 2019-12-31Target: 720Updated: 2019-10-04

Xingnaojing for Mild-to-severe Acute Ischemic Stroke

Dongzhimen Hospital, BeijingAcute Ischemic Stroke, Stroke, Acute, Stroke, Ischemic

Start: 2020-03-19End: 2021-12-31Target: 1200Updated: 2021-04-01

Analyzing the Pharmacodynamic Substances and the Effects of Xingnaojing for Mild-to-Severe Acute Ischemic Stroke

Ying GaoIschemic Stroke, Acute

Start: 2022-08-16End: 2023-03-31Target: 20Updated: 2022-09-29

Unknown Phase

Analysing the Effects of Xingnaojing for Mild-to-severe Acute Ischemic Stroke

Dongzhimen Hospital, BeijingAcute Stroke, Ischemic Stroke

Start: 2021-05-28End: 2022-09-28Target: 72Updated: 2022-02-18

Related Papers

China Stroke Registry for Patients With Traditional Chinese Medicine (CASES-TCM): Rationale and Design of a Prospective, Multicenter, Observational Study.

2021-08-318 citations

Xingnaojing for Moderate-to-severe Acute ischemic Stroke (XMAS): study protocol for a randomized controlled trial

Trials2017-10-1611 citations